Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer

Frontiers in Physiology(2020)10.3389/fphys.2020.583333Source: DataRank Database

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer is a research paper published in Frontiers in Physiology (2020). On theSindex it has a DataRank of 0. It has been cited 79 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access79 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 4.33)OA: goldTopics (24)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Chang Gong ORCID,Jeremias Sulam ORCID,Elana J. Fertig ORCID,Alexander S. Szalay ORCID,Elizabeth M. Jaffee ORCID

Live enrichment

PubMed:33192595 PMC:PMC7604437 OpenAlex:https://openalex.org/W3093154039

National Institutes of Health

Grant: R01CA138264

National Institutes of Health

Grant: U01CA212007

FWCI

4.33

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fphys.2020.583333

publisherhttps://doi.org/10.3389/fphys.2020.583333

publisherhttps://www.frontiersin.org/articles/10.3389/fphys.2020.583333/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33192595

repositoryhttps://doaj.org/article/661ed5204e1a42009d6a3f5cc131bda4

Fields of Study

Cancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomicsCancer Cells and Metastasis

Keywords

Digital pathologyFOXP3Triple-negative breast cancerImmune systemCD8Tumor microenvironmentCD20Breast cancerBiologyPathologyCD3CancerImmunologyMedicineAntigenGeneticsSpatial patternsTumor HeterogeneityImage InformaticsQupathImmuno-architecture

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 10 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193756.v1figshare

Additional file 10 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193756figshare

Additional file 11 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193762.v1figshare

Additional file 11 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193762figshare

Additional file 12 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193768.v1figshare

Additional file 12 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193768figshare

Additional file 13 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193771.v1figshare

Additional file 13 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193771figshare

Additional file 14 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193774.v1figshare

Additional file 14 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193774figshare

Additional file 15 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193780.v1figshare

Additional file 15 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193780figshare

Additional file 1 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193783.v1figshare

Additional file 1 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193783figshare

Additional file 2 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193786.v1figshare

Additional file 2 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193786figshare

Additional file 3 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193792.v1figshare

Additional file 3 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193792figshare

Additional file 4 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193798.v1figshare

Additional file 4 of Ceritinib is a novel triple negative breast cancer therapeutic agent

10.6084/m9.figshare.20193798figshare

Related Papers (8)

T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III

Archives of Gynecology and Obstetrics(2008)

OpenAlex related

10.1007/s00404-008-0621-8

Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder

American Journal of Dermatopathology(2015)

OpenAlex related

10.1097/dad.0000000000000323

Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group

Journal of the Korean Surgical Society(2009)

OpenAlex related

10.4174/jkss.2009.77.1.37

Abstract P3-05-20: A study on amount, localization and immune phenotype of tumor-infiltrating lymphocytes in different subtypes of breast cancer

Cancer Research(2018)

OpenAlex related

10.1158/1538-7445.sabcs17-p3-05-20

COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS

Journal of Evolution of Medical and Dental Sciences(2018)

OpenAlex related

10.14260/jemds/2018/770

Treatment of triple negative breast cancer

Guoji zhongliuxue zazhi(2013)

OpenAlex related

10.3760/cma.j.issn.1673-422x.2013.09.013

Supplementary Table 3 from Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study

(2023)

OpenAlex related

10.1158/1078-0432.22460277

Comparison of ultrasound features and establishment of a predictive nomogram for triple-negative and non-triple-negative breast cancer

Research Square(2024)

OpenAlex related

10.21203/rs.3.rs-3936899/v1